A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

To join this study, you would typically need to have advanced non-small cell lung cancer that hasn't been treated with previous medicines for its advanced stage. Doctors would need to be able to measure your cancer on scans like CT or MRI. You also need to be well enough to take part in the study, meaning you are generally active and able to perform daily tasks with ease.

There are also some specific medical requirements, such as having certain levels of a marker called PD-L1 in your cancer cells. Researchers will test for this. Your body's organs and blood counts also need to be working well enough to safely receive the treatment.

Certain conditions would prevent you from joining the study. For example, if you have active or untreated cancer spread to your brain or spinal cord, or if you've never smoked (defined as smoking 100 cigarettes or less in your lifetime).

If you decide to join this study, you'll receive either the combination of fianlimab and cemiplimab, or cemiplimab on its own. The treatments are usually given through a drip (intravenous infusion). You would have regular visits to the clinic for these treatments and for check-ups, which include blood tests, physical exams, and scans to monitor your cancer. Researchers will also ask you questions about how you're feeling and your quality of life. The exact number of visits and the full duration of your participation will be discussed in detail by the study team, but it will involve ongoing assessments and follow-up.